Aciex issued patents for allergic conjunctivitis, postoperative inflammation agents

Aciex Therapeutics announced that the United States Patent and Trademark Office has issued two separate U.S. patents for compositions within the allergy and ophthalmic market.Patent No. 8,829,005 covers compositions of AC-170, a novel formulation of the oral antihistamine cetirizine ophthalmic solution 0.24%, which is being evaluated for the treatment of allergic conjunctivitis. A pre-New Drug Application meeting with the U.S. Food and Drug Administration is expected to occur by the end of the first quarter in 2015, according to a press release from Aciex.